Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

By sjmartinez • June 13, 2025

Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS. Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection. Mol Ther Methods Clin Dev. 2025 May 15;33(2):101486. doi: 10.1016/j.omtm.2025.101486. PMID: 40503012; PMCID: PMC12152878.

Tags: C46 membrane-anchored HIV-1 fusion inhibitor, CCR5 short hairpin RNA, CD4-based anti-HIV-1 chimeric antigen receptor, cetuximab-mediated in vivo negative selection, Hematology/Oncology, hematopoietic stem/progenitor cell-based gene therapy, HIV-1, HSPC, huEGFRt, humanized mouse, Publications, truncated human EGFR

Access to AlloTx for AML: the value of the social phenotype

Schiller G. Access to AlloTx for AML: the value of the social phenotype. Blood. 2025 Jun 19;145(25):2941-2942. doi: 10.1182/blood.2025028826. PMID: 40536784.

Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality in Vital Statistics

Bor J, Bird M, Hakes JK, Himmelstein DU, Himmelstein G, Woolhandler S. Life Expectancy of American Indian and Alaska Native Persons and Underreporting of Mortality[...]

Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report and Literature Review

Tai JW, Roufeh EN, Reed JP. Primary Cardiac Diffuse Large B-Cell Lymphoma Managed With Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report[...]